An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants

Summary

The purpose of this phase III study is to evaluate the immunogenicity and safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) in 2-month-old infants.

Timeline

Start

2017-08-08

Primary completion

2017-10-18

Completion

2018-04-18

Outcome

Met primary endpoint

paper The sIPV demonstrated an immunogenicity profile noninferior to that of the conventional IPV and had a good safety profile. PMID 30958543 ↗

Publications

• Hu Y, Wang J, Zeng G, Chu K, Jiang D, Zhu F, Ying Z, Chen L, Li C, Zhu F, Yin W. Immunogenicity and Safety of a Sabin Strain-Based Inactivated Polio Vaccine: A Phase 3 Clinical Trial. J Infect Dis. 2019 Oct 8;220(10):1551-1557. doi: 10.1093/infdis/jiy736.

Drugs

Indications